C2N Diagnostics, LLC has secured a significant $15 million investment from the GHR Foundation to advance the development of next-generation Alzheimer's disease tests that focus on tau tangle pathology.

The new blood test will utilize tau-based biomarkers, including MTBR-tau, which are crucial for diagnosing Alzheimer's, staging its progression, and supporting tau-directed treatments.

Dr. Howard Fillit, Chief Science Officer of the Alzheimer's Drug Discovery Foundation, emphasized the importance of C2N's blood tests in making diagnostic testing more affordable and accessible for Alzheimer's care.

C2N Diagnostics aims to elevate the standards of Alzheimer's diagnosis through innovative testing solutions, as highlighted by their CEO, Dr. Joel Braunstein.

Tau tangles are critical components of Alzheimer's disease pathology and are linked to the clinical progression of the disease.

C2N's existing PrecivityAD2 blood test has demonstrated a 90% accuracy rate in diagnosing Alzheimer's, as supported by research published in the Journal of the American Medical Association.

In addition to the GHR Foundation's investment, C2N received up to $7 million from the Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator to develop a decentralized clinical mass spectrometry platform for scalable Alzheimer's testing.

This new mass spectrometry platform will track both amyloid and tau pathology, with the potential to incorporate future assays for other neurodegenerative diseases.

C2N has established partnerships with major clinical diagnostic labs globally, including Unilabs in Europe and Grupo Fleury in Brazil, to expand access to testing.

The company has participated in over 150 research studies related to Alzheimer's disease and continues to collaborate with various organizations to enhance public health.

This latest investment follows a previous $7.025 million grant from the Alzheimer's Drug Discovery Foundation aimed at improving Alzheimer's testing through mass spectrometry.

Since 2020, the GHR Foundation has invested a total of $50 million in C2N, underscoring their commitment to advancing Alzheimer's diagnostics.